What are adverse effects of topical immunotherapy for alopecia areata?

Updated: Aug 06, 2020
  • Author: Chantal Bolduc, MD, FRCPC; Chief Editor: Dirk M Elston, MD  more...
  • Print

Adverse effects include cervical lymphadenopathy and pigment changes. Vitiligo developed on the application site in 6.7-7.5% of patients. Transient leukoderma on a distant untreated area has been reported. Of patients who develop vitiligo, 31% (4 of 13) had a history of vitiligo. Only 0.75% of patients developed hyperpigmentation. Confetti-type dyschromia (ie, hyperpigmentation, hypopigmentation) has been described as an adverse effect of DPCP treatment and occurred in 1.6% of 243 patients treated. Less common adverse effects include erythema multiforme–like eruptions and urticaria, which were reported in 3 patients treated with DPCP.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!